Single Center Experience with a 4-Week 177 Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer.

Jukka KemppainenAki KangasmäkiSimona MalaspinaBernd PapeJarno JalomäkiKalevi KairemoJuha KononenTimo Joensuu

Published in: Cancers (2022)

Lu-PSMA-617 treatment in four-week intervals was safe and effective. Almost 60% of patients had a significant PSA response, which was associated with better OS. Pre-treatment PSA kinetics or staging PSMA PET/CT-derived parameters were not helpful in identifying treatment responders from non-responders; better biomarkers are needed to aid in patient selection.

Keyphrases

pet ct
prostate cancer
randomized controlled trial
clinical trial
newly diagnosed
end stage renal disease
pet imaging
positron emission tomography
computed tomography
replacement therapy
prognostic factors
double blind
patient reported outcomes